See more : Nongfu Spring Co., Ltd. (NNFSF) Income Statement Analysis – Financial Results
Complete financial analysis of MDxHealth SA (MDXH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MDxHealth SA, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Tribe Property Technologies Inc. (TRBE.V) Income Statement Analysis – Financial Results
- EMS-CHEMIE HOLDING AG (EMSN.SW) Income Statement Analysis – Financial Results
- Rite Aid Corporation (RADCQ) Income Statement Analysis – Financial Results
- Canadian Tire Corporation, Limited (CTC.TO) Income Statement Analysis – Financial Results
- Toagosei Co., Ltd. (4045.T) Income Statement Analysis – Financial Results
MDxHealth SA (MDXH)
About MDxHealth SA
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 70.19M | 37.05M | 22.24M | 18.37M | 11.79M | 28.34M | 40.51M | 29.87M | 17.47M | 11.48M | 7.55M | 4.92M | 3.48M | 3.37M | 3.65M | 4.21M | 3.85M | 3.66M | 3.65M | 525.97K |
| Cost of Revenue | 26.26M | 17.84M | 11.83M | 10.52M | 11.93M | 11.65M | 10.20M | 10.10M | 6.91M | 6.45M | 5.79M | 1.19M | 344.76K | 492.09K | 256.46K | 338.28K | 656.10K | 72.59K | 135.02K | 12.20K |
| Gross Profit | 43.93M | 19.22M | 10.41M | 7.85M | -144.00K | 16.69M | 30.31M | 19.76M | 10.56M | 5.03M | 1.76M | 3.72M | 3.14M | 2.88M | 3.39M | 3.87M | 3.19M | 3.58M | 3.51M | 513.77K |
| Gross Profit Ratio | 62.58% | 51.87% | 46.82% | 42.72% | -1.22% | 58.88% | 74.81% | 66.17% | 60.47% | 43.78% | 23.31% | 75.72% | 90.10% | 85.41% | 92.97% | 91.96% | 82.96% | 98.02% | 96.30% | 97.68% |
| Research & Development | 6.38M | 7.56M | 6.67M | 4.54M | 9.00M | 1.81M | 1.83M | -332.00K | 2.10M | 742.00K | 1.58M | 3.29M | 6.23M | 9.06M | 18.75M | 15.31M | 15.60M | 11.41M | 6.85M | 6.23M |
| General & Administrative | 23.01M | 23.54M | 5.07M | 4.15M | 5.68M | 6.19M | 5.35M | 3.95M | 2.97M | 2.50M | 1.86M | 1.80M | 6.20M | 4.98M | 5.75M | 4.33M | 3.59M | 2.50M | 1.80M | 1.40M |
| Selling & Marketing | 36.92M | 26.58M | 2.59M | 2.31M | 4.43M | 9.07M | 8.15M | 7.61M | 6.02M | 4.91M | 2.50M | 2.95M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 59.93M | 50.12M | 7.65M | 6.46M | 10.10M | 15.26M | 13.51M | 11.56M | 8.99M | 7.40M | 4.36M | 4.75M | 6.20M | 4.98M | 5.75M | 4.33M | 3.59M | 2.50M | 1.80M | 1.40M |
| Other Expenses | 4.96M | -559.00K | 22.93M | 23.97M | 23.92M | 31.71M | 27.25M | 21.39M | 13.85M | 12.22M | 11.90M | 7.46M | -93.32K | -33.25K | 0.00 | 1.39K | -77.27K | -242.84K | -72.25K | -67.78K |
| Operating Expenses | 71.26M | 57.12M | 37.25M | 34.97M | 43.03M | 48.78M | 42.58M | 32.61M | 24.94M | 20.37M | 17.83M | 15.50M | 12.34M | 14.01M | 24.50M | 19.64M | 19.25M | 14.18M | 8.72M | 7.70M |
| Cost & Expenses | 97.52M | 74.95M | 49.08M | 45.50M | 54.95M | 60.44M | 52.78M | 42.71M | 31.85M | 26.82M | 23.63M | 16.70M | 12.68M | 14.50M | 24.76M | 19.98M | 19.91M | 14.25M | 8.86M | 7.71M |
| Interest Income | 1.09M | 125.00K | 11.00K | 4.00K | 10.00K | 21.00K | 0.00 | 6.00K | 13.00K | 14.00K | 16.00K | 87.29K | 277.36K | 295.25K | 644.74K | 1.59M | 1.53M | 868.43K | 138.57K | 146.40K |
| Interest Expense | 5.58M | 6.14M | 1.88M | 1.35M | 318.00K | 82.00K | 0.00 | 0.00 | 99.00K | 23.00K | 20.00K | 357.08K | 82.95K | 113.05K | 28.65K | 12.53K | 1.61M | 1.11M | 210.82K | 214.19K |
| Depreciation & Amortization | 6.86M | 4.91M | 3.04M | 3.33M | 3.42M | 2.94M | 2.21M | 1.72M | 881.00K | 333.00K | 418.00K | 527.68K | 397.90K | 462.83K | 3.29M | 1.40M | 839.81K | 497.56K | 280.70K | 325.34K |
| EBITDA | -30.47M | -36.39M | -23.99M | -23.79M | -39.74M | -29.47M | -10.19M | -11.57M | -13.50M | -14.88M | -15.59M | -9.80M | -9.22M | -10.37M | -16.66M | -13.43M | -12.86M | -8.77M | -4.93M | -6.86M |
| EBITDA Ratio | -43.41% | -89.03% | -107.46% | -130.55% | -338.88% | -104.00% | -24.88% | -37.25% | -77.29% | -130.33% | -203.20% | -228.77% | -244.73% | -307.41% | -470.29% | -303.54% | -395.27% | -276.04% | -135.09% | -1,304.64% |
| Operating Income | -27.33M | -37.90M | -26.84M | -27.12M | -43.17M | -32.10M | -12.27M | -12.85M | -14.38M | -15.34M | -16.07M | -11.78M | -9.20M | -11.13M | -21.11M | -15.77M | -16.00M | -10.35M | -5.14M | -7.12M |
| Operating Income Ratio | -38.93% | -102.28% | -120.69% | -147.63% | -366.30% | -113.27% | -30.30% | -43.01% | -82.34% | -133.65% | -212.75% | -239.50% | -264.12% | -329.89% | -578.14% | -374.54% | -415.41% | -283.00% | -140.80% | -1,353.61% |
| Total Other Income/Expenses | -15.77M | -6.14M | -2.16M | -1.54M | -506.00K | -393.00K | -127.00K | -441.00K | -91.00K | 86.00K | -104.00K | -89.00K | 209.00K | 182.21K | 616.08K | 853.66K | 1.45M | 625.59K | -180.88K | 78.62K |
| Income Before Tax | -43.10M | -44.04M | -29.00M | -28.66M | -43.68M | -32.49M | -12.40M | -13.29M | -14.47M | -15.26M | -16.18M | -11.87M | -9.00M | -10.94M | -20.49M | -14.19M | -14.54M | -9.72M | -5.07M | -7.04M |
| Income Before Tax Ratio | -61.40% | -118.86% | -130.41% | -156.01% | -370.60% | -114.66% | -30.61% | -44.49% | -82.86% | -132.90% | -214.12% | -241.36% | -258.54% | -324.49% | -561.26% | -337.04% | -377.70% | -265.90% | -138.98% | -1,338.66% |
| Income Tax Expense | 1.00K | 6.14M | 1.88M | 1.35M | -575.00K | -41.00K | -113.00K | -113.00K | 86.00K | 9.00K | 4.00K | 91.25K | -194.41K | 31.92K | -616.08K | -1.58M | -1.61M | -1.11M | -210.82K | -214.19K |
| Net Income | -43.10M | -50.19M | -30.88M | -30.01M | -43.10M | -32.45M | -12.29M | -13.17M | -14.47M | -15.26M | -16.18M | -11.87M | -9.00M | -10.98M | -20.49M | -14.19M | -14.54M | -9.72M | -5.07M | -7.04M |
| Net Income Ratio | -61.40% | -135.45% | -138.84% | -163.33% | -365.72% | -114.51% | -30.33% | -44.11% | -82.86% | -132.90% | -214.12% | -241.36% | -258.54% | -325.43% | -561.26% | -337.04% | -377.70% | -265.90% | -138.98% | -1,338.66% |
| EPS | -1.66 | -3.16 | -2.53 | -3.61 | -6.89 | -5.63 | -2.46 | -2.86 | -3.51 | -4.39 | -5.38 | -5.38 | -5.23 | -8.32 | -15.55 | -11.98 | -13.46 | -11.33 | -11.10 | -18.76 |
| EPS Diluted | -1.66 | -3.16 | -2.53 | -3.61 | -6.89 | -5.63 | -2.46 | -2.86 | -3.51 | -4.39 | -5.38 | -5.38 | -5.23 | -8.32 | -15.55 | -11.98 | -13.46 | -11.33 | -11.10 | -18.76 |
| Weighted Avg Shares Out | 25.91M | 15.87M | 12.19M | 8.32M | 6.26M | 5.76M | 4.99M | 4.61M | 4.13M | 3.48M | 3.00M | 2.21M | 1.72M | 1.32M | 1.32M | 1.18M | 1.08M | 857.92K | 456.88K | 375.28K |
| Weighted Avg Shares Out (Dil) | 25.91M | 15.87M | 12.19M | 8.32M | 6.26M | 5.76M | 4.99M | 4.61M | 4.13M | 3.48M | 3.00M | 2.21M | 1.72M | 1.32M | 1.32M | 1.18M | 1.08M | 857.92K | 456.88K | 375.28K |
MDxHealth Announces Proposed Transition to a Sole Listing of Shares on Nasdaq and Convenes an Extraordinary General Shareholders Meeting
NEWS RELEASE – REGULATED INFORMATION INSIDE INFORMATION OCTOBER 2, 2023, 4:00pm ET / 22:00 CET
Mdxhealth Signs Research Collaboration with University of Oxford to Assess the Correlation of the GPS Test with Prostate Cancer Progression Following Treatment for Localized Prostate Cancer
NEWS RELEASE September 26 , 202 3 , 5 :00PM EDT / 23:00 CET
MDxHealth SA (MXDHF) Q2 2023 Earnings Call Transcript
MDxHealth SA (OTC:MXDHF) Q2 2023 Earnings Call Transcript August 23, 2023 4:30 PM ET Company Participants Michael McGarrity - Chief Executive Officer Ron Kalfus - Chief Financial Officer Conference Call Participants Dan Brennan - TD Cowen Andrew Brackmann - William...
MDxHealth SA Sponsored ADR (MDXH) Reports Q2 Loss, Tops Revenue Estimates
MDxHealth SA Sponsored ADR (MDXH) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.70 per share a year ago.
MDxHealth Reports Q2 and Half Year 2023 Results
NEWS RELEASE – REGULATED INFORMATION 23 AUGUST 202 3 , 4:00PM EDT / 22:00 CET
MDxHealth to Present Q2 and Half Year 2023 Financial Results and Corporate Update on August 23
NEWS RELEASE 10 AUGUST 202 3 , 4 PM ET / 22:00 CET
Cigna Expands Commercial and Medicare Advantage Coverage to Include Mdxhealth's Select mdx for Prostate Cancer Test
Expansion of coverage with Cigna now includes full menu of Company's precision diagnostic prostate cancer tests, representing more than 15 million lives under coverage.
MDxHealth to Present at the 43rd Annual William Blair Growth Stock Conference
NEWS RELEASE May 23 , 2023, 4 PM ET/ 22: 0 0 CET MDxHealth to Present at the 43 rd Annual William Blair Growth Stock Conference IRVINE, CA, and HERSTAL, BELGIUM – May 23, 2023 – MDxHealth SA (Nasdaq and...
MDxHealth SA (MXDHF) Q1 2023 Earnings Call Transcript
MDxHealth SA (OTC:MXDHF) Q1 2023 Earnings Conference Call May 15, 2023 4:30 AM ET Company Participants Michael McGarrity - Chief Executive Officer Ron Kalfus - Chief Financial Officer Conference Call Participants Andrew Brackmann - William Blair Thomas Vranken - KBC...
MDxHealth SA Sponsored ADR (MDXH) Reports Q1 Loss, Tops Revenue Estimates
MDxHealth SA Sponsored ADR (MDXH) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.05 per share a year ago.
Source: https://incomestatements.info
Category: Stock Reports